🔎 Trials Near Me

Pradžia › Opinis kolitas › Texas › Tyler

Opinis kolitas klinikiniai tyrimai Tyler, TX

14 tyrimai dėl Opinis kolitas ieško dalyvių vietose Tyler ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.

Oficialus tyrimo tekstas (anglų kalba)

Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Renkami dalyviai3 fazė
  • Tyler Research Institute ( Site 0294), Tyler
Visi amžiai · Visoms lytims · Atnaujinta 2026-10-02 · NCT06651281

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Renkami dalyviai2 fazė
  • Tyler Research Institute, Tyler
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-30 · NCT06598943

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Renkami dalyviai1/2 fazėLaukiami sveiki savanoriai
  • Xencor Investigative Site, Tyler
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-29 · NCT06619990

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

Renkami dalyviai2 fazė
  • Site US-004, Tyler
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-29 · NCT07845487

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Renkami dalyviai3 fazė
  • Tyler Research Institute, LLC, Tyler
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07196748

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Renkami dalyviai3 fazė
  • Tyler Research Institute, Tyler
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-24 · NCT06937086

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Renkami dalyviai2 fazė
  • Tyler Research Institute, Tyler
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07186101

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Renkami dalyviai2 fazė
  • Tyler Research Institute, Tyler
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07415044

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Renkami dalyviai4 fazė
  • Tyler Research Institute, LLC, Tyler
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-21 · NCT06095128

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Renkami dalyviai3 fazė
  • Tyler Research Institute, LLC - Site Number: 8400095, Tyler
Amžius nuo 16 iki 80 · Visoms lytims · Atnaujinta 2026-09-15 · NCT07185009

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

Renkami dalyviai3 fazė
  • Tyler Research Institute, LLC, Tyler
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-28 · NCT07577856

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Renkami dalyviai3 fazė
  • Tyler Research Institute, LLC - Site Number: 8400095, Tyler
Amžius nuo 16 iki 80 · Visoms lytims · Atnaujinta 2026-08-20 · NCT07184996

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

Renkami dalyviai2 fazė
  • Tyler Research Institute, LLC, Tyler
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-05-22 · NCT06764615

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

Renkami dalyviai2 fazė
  • Mirador Therapeutics Selected Site, Tyler
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-03-12 · NCT07113522

Opinis kolitas tyrimai kituose miestuose

Kiti tyrimai Tyler

Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.